This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eto, Y. Articles by Aoyagi, T. Search for Related Content PubMed PubMed Citation Articles by Eto, Y. Articles by Aoyagi, T. Related Collections Hypertrophy

(Circulation. 2000;101:2134.)
© 2000 American Heart Association, Inc.

Brief Rapid Communication

Calcineurin Is Activated in Rat Hearts With Physiological Left Ventricular Hypertrophy Induced by Voluntary Exercise Training

Yoko Eto, MD; Katsunori Yonekura, MD; Makoto Sonoda, MD; Naoto Arai, MD; Masataka Sata, MD; Seiryo Sugiura, MD; Katsu Takenaka, MD; Antonio Gualberto, MD, PhD; Mary L. Hixon, MS, PhD; Mark W. Wagner, BA; Teruhiko Aoyagi, MD

From the Department of Cardiovascular Medicine (Y.E., K.Y., M.Sonoda, N.A., M.Sata, S.S., K.T., T.A.), University of Tokyo, Tokyo, Japan, and the Department of Physiology and Biophysics (A.G., M.L.H., M.W.W.), Case Western Reserve University, Cleveland, Ohio. Present address of Antonio Gualberto is Department of Cardiovascular & Metabolic Disease, Pfizer Central Research Division, Groton, CT 06340.

Correspondence to Teruhiko Aoyagi, MD, Department of Cardiovascular Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. E-mail aoyagi-2im{at}h.u-tokyo.ac.jp

Background—Calcineurin may play a pivotal role in the signaling of cardiac hypertrophy; since this hypothesis was first put forward, controversial reports have been published using various experimental models. This study was designed to compare the physiological left ventricular hypertrophy (LVH) induced by voluntary exercise with LVH induced by aortic constriction and to determine whether calcineurin participates in the signaling of exercise-induced LVH.

Methods and Results—Wistar rats were assigned to 1 of the following 5 groups: 10 weeks of voluntary exercise (EX), a sedentary regimen, a 1-week (AC1) or 4-week (AC4) ascending aortic constriction period, or a sham operation. EX rats ran 2.4±0.7 km/day voluntarily in specially manufactured cages; this was associated with an increase of LV diastolic dimension and stroke volume. Myocardial calcineurin activity markedly increased in EX rats (46.4±8.3 versus 18.4±0.5 pmol · min^-1 · mg^-1 in sedentary rats; P<0.001) and in AC1 rats (44.9±6.7 versus 22.1±3.7 pmol · min^-1 · mg^-1 in sham-operated rats; P<0.001), but not in AC4 rats (29.0±3.4 pmol · min^-1 · mg^-1). Treatment with cyclosporin A completely inhibited the development of LVH in EX rats, but it only partially attenuated the development of LVH in AC4 rats.

Conclusions—Calcineurin was activated in exercise-induced physiological LVH and in the developing phase of LVH (AC1), but not in decompensated pressure-overload hypertrophy (AC4). Cyclosporin therapy for the prevention of LVH may be harmful because it does not block the development of pathological hypertrophy but rather that of favorable adaptive hypertrophy.

Key Words: exercise • hypertrophy • signal transduction

This article has been cited by other articles:

				S. C. Kolwicz, S. M. MacDonnell, B. F. Renna, P. O. Reger, R. Seqqat, K. Rafiq, Z. V. Kendrick, S. R. Houser, A. Sabri, and J. R. Libonati Left ventricular remodeling with exercise in hypertension Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1361 - H1368. [Abstract] [Full Text] [PDF]

				F. Bogazzi, D. Russo, F. Raggi, F. Ultimieri, C. Urbani, M. Gasperi, L. Bartalena, and E. Martino Transgenic Mice Overexpressing Growth Hormone (GH) Have Reduced or Increased Cardiac Apoptosis through Activation of Multiple GH-Dependent or -Independent Cell Death Pathways Endocrinology, November 1, 2008; 149(11): 5758 - 5769. [Abstract] [Full Text] [PDF]

				J. Boissiere, V. Eder, M.-C. Machet, D. Courteix, and P. Bonnet Moderate exercise training does not worsen left ventricle remodeling and function in untreated severe hypertensive rats J Appl Physiol, February 1, 2008; 104(2): 321 - 327. [Abstract] [Full Text] [PDF]

				M. Sakamoto, T. Minamino, H. Toko, Y. Kayama, Y. Zou, M. Sano, E. Takaki, T. Aoyagi, K. Tojo, N. Tajima, et al. Upregulation of Heat Shock Transcription Factor 1 Plays a Critical Role in Adaptive Cardiac Hypertrophy Circ. Res., December 8, 2006; 99(12): 1411 - 1418. [Abstract] [Full Text] [PDF]

				J. P. Konhilas, U. Widegren, D. L. Allen, A. C. Paul, A. Cleary, and L. A. Leinwand Loaded wheel running and muscle adaptation in the mouse Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H455 - H465. [Abstract] [Full Text] [PDF]

				P. J. Schaeffer, A. R. Wende, C. J. Magee, J. R. Neilson, T. C. Leone, F. Chen, and D. P. Kelly Calcineurin and Calcium/Calmodulin-dependent Protein Kinase Activate Distinct Metabolic Gene Regulatory Programs in Cardiac Muscle J. Biol. Chem., September 17, 2004; 279(38): 39593 - 39603. [Abstract] [Full Text] [PDF]

				G. Selvetella, E. Hirsch, A. Notte, G. Tarone, and G. Lembo Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence Cardiovasc Res, August 15, 2004; 63(3): 373 - 380. [Abstract] [Full Text] [PDF]

				J. D Molkentin Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs Cardiovasc Res, August 15, 2004; 63(3): 467 - 475. [Abstract] [Full Text] [PDF]

				P. Tavi, S. Pikkarainen, J. Ronkainen, P. Niemela, M. Ilves, M. Weckstrom, O. Vuolteenaho, J. Bruton, H. Westerblad, and H. Ruskoaho Pacing-induced calcineurin activation controls cardiac Ca2+ signalling and gene expression J. Physiol., January 15, 2004; 554(2): 309 - 320. [Abstract] [Full Text] [PDF]

				B. J. Wilkins, Y.-S. Dai, O. F. Bueno, S. A. Parsons, J. Xu, D. M. Plank, F. Jones, T. R. Kimball, and J. D. Molkentin Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy Circ. Res., January 9, 2004; 94(1): 110 - 118. [Abstract] [Full Text] [PDF]

				K. A. Matthews, B. B. Gump, K. F. Harris, T. L. Haney, and J. C. Barefoot Hostile Behaviors Predict Cardiovascular Mortality Among Men Enrolled in the Multiple Risk Factor Intervention Trial Circulation, January 6, 2004; 109(1): 66 - 70. [Abstract] [Full Text] [PDF]

				J. Li, A. Yatani, S.-J. Kim, G. Takagi, K. Irie, Q. Zhang, V. Karoor, C. Hong, G. Yang, J. Sadoshima, et al. Neurally-mediated increase in calcineurin activity regulates cardiac contractile function in absence of hypertrophy Cardiovasc Res, September 1, 2003; 59(3): 649 - 657. [Abstract] [Full Text] [PDF]

				S. Mitsuhashi, N. Saito, K. Watano, K. Igarashi, S. Tagami, H. Shima, and K. Kikuchi Defect of Delta-Sarcoglycan Gene Is Responsible for Development of Dilated Cardiomyopathy of a Novel Hamster Strain, J2N-k: Calcineurin/PP2B Activity in the Heart of J2N-k Hamster J. Biochem., August 1, 2003; 134(2): 269 - 276. [Abstract] [Full Text] [PDF]

				J. L. Gooch, J. L. Barnes, S. Garcia, and H. E. Abboud Calcineurin is activated in diabetes and is required for glomerular hypertrophy and ECM accumulation Am J Physiol Renal Physiol, January 1, 2003; 284(1): F144 - F154. [Abstract] [Full Text] [PDF]

				B. J. Wilkins, L. J. De Windt, O. F. Bueno, J. C. Braz, B. J. Glascock, T. F. Kimball, and J. D. Molkentin Targeted Disruption of NFATc3, but Not NFATc4, Reveals an Intrinsic Defect in Calcineurin-Mediated Cardiac Hypertrophic Growth Mol. Cell. Biol., November 1, 2002; 22(21): 7603 - 7613. [Abstract] [Full Text] [PDF]

				F. W Booth, M. V Chakravarthy, and E. E Spangenburg Exercise and gene expression: physiological regulation of the human genome through physical activity J. Physiol., September 1, 2002; 543(2): 399 - 411. [Abstract] [Full Text] [PDF]

				O. Ritter, S. Hack, K. Schuh, N. Rothlein, A. Perrot, K. J. Osterziel, H. D. Schulte, and L. Neyses Calcineurin in Human Heart Hypertrophy Circulation, May 14, 2002; 105(19): 2265 - 2269. [Abstract] [Full Text] [PDF]

				O. F Bueno, E. van Rooij, J. D Molkentin, P. A Doevendans, and L. J De Windt Calcineurin and hypertrophic heart disease: novel insights and remaining questions Cardiovasc Res, March 1, 2002; 53(4): 806 - 821. [Abstract] [Full Text] [PDF]

				W. Zhang Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy Cardiovasc Res, February 1, 2002; 53(2): 294 - 303. [Abstract] [Full Text] [PDF]

				M. A. Perhonen, F. Franco, L. D. Lane, J. C. Buckey, C. G. Blomqvist, J. E. Zerwekh, R. M. Peshock, P. T. Weatherall, and B. D. Levine Cardiac atrophy after bed rest and spaceflight J Appl Physiol, August 1, 2001; 91(2): 645 - 653. [Abstract] [Full Text] [PDF]

				L. J. De Windt, H. W. Lim, O. F. Bueno, Q. Liang, U. Delling, J. C. Braz, B. J. Glascock, T. F. Kimball, F. del Monte, R. J. Hajjar, et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy invivo PNAS, March 13, 2001; 98(6): 3322 - 3327. [Abstract] [Full Text] [PDF]

				B. A. Rothermel, T. A. McKinsey, R. B. Vega, R. L. Nicol, P. Mammen, J. Yang, C. L. Antos, J. M. Shelton, R. Bassel-Duby, E. N. Olson, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo PNAS, March 13, 2001; 98(6): 3328 - 3333. [Abstract] [Full Text] [PDF]

				J. D. Molkentin Calcineurin and Beyond : Cardiac Hypertrophic Signaling Circ. Res., October 27, 2000; 87(9): 731 - 738. [Abstract] [Full Text] [PDF]

				K. Kinugawa, K. Yonekura, R. C.J. Ribeiro, Y. Eto, T. Aoyagi, J. D. Baxter, S. A. Camacho, M. R. Bristow, C. S. Long, and P. C. Simpson Regulation of Thyroid Hormone Receptor Isoforms in Physiological and Pathological Cardiac Hypertrophy Circ. Res., September 28, 2001; 89(7): 591 - 598. [Abstract] [Full Text] [PDF]